[1] Revill PA, Penicaud C, Brechot Christian, et al. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes (Basel). 2019;10:undefined.
[2] Schweitzer A, Horn J, Mikolajczyk R T, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-1555.
[3] Liu J, Liang WN, Jing WZ, et al. Countdown to 2030: eliminating hepatitis B disease, China. Bull, World Health Organ. 2019;97:230-238.
[4] Vittal A, Ghany M G. WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. Clin Liver Dis. 2019;23:417-432.
[5] Stanaway J D, Flaxman A D, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081-1088.
[6] Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut. 2012;2:16-17.
[7] World Health Statistics 2018: Monitoring health for the SDGs. WHO. 2018;6 June.
[8] Bhattacharya D, Thio C L, Reviewof. Hepatitis B therapeutics. Clin Infect Dis. 2010;51:1201-1208.
[9] Shan S, Jia J. Advances and challenge in prevention and treatment of hepatitis B in China. Zhongguo Bingdubing Zazhi. 2017;01:5–8.
[10] Subic M, Zoulim F. How to improve access to therapy in hepatitis B patients. Liver Int. 2018;38 Suppl 1:115–121.
[11]Yuen Man F, Gane Edward J, Kim Dong J, et al. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection. Gastroenterology. 2019;156:1392-1403.
[12]Calvaruso V, Craxì A. Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? Liver Int. 2014;85-90.
[13]Sun D J, Zhu L J, Yao D H, et al. Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives. Eur J Med Chem. 2018;147:205-217.
[14]Lee S H, Cheon G J, Kim H S, et al. Tenofovir disoproxil fumarate monotherapy is superior to entecavir-adefovir combination therapy in patients with suboptimal response to lamivudine-adefovir therapy for nucleoside-resistant HBV: a 96-week prospective multicenter trial. Antiviral Therapy. 2018;23:219-227.
[15]Tsai T Y, Livneh H, Hung T H, et al. Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open. 2017;7:e014571.
[16]Zhao Y , Geng C A, Ma Y B, et al. UFLC/MS-IT-TOF guided isolation of anti-HBV active chlorogenic acid analogues from Artemisia capillaris as a traditional Chinese herb for the treatment of hepatitis. J Ethnopharmacol. 2014;156:147-154.
[17]Han J M, Kim H G, Choi M K, et al. Artemisia capillaris extract protects against bile duct ligation-induced liver fibrosis in rats. Exp Toxicol Pathol. 2013;65:837-844.
[18]Zhao T T, Tang H L, Xie L, et al. Scutellaria baicalensis Georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. J Pharm Pharmacol. 2019;71:1353-1369.
[19]Park H S, Park K I, Hong G E, et al. Korean Scutellaria baicalensis Georgi methanol extracts inhibits metastasis via the Forkhead Box M1 activity in hepatocellular carcinoma cells. J Ethnopharmacol. 2014;155:847-851.
[20]Hsu Y L, Kuo P L, Tzeng T F, et al. Huang-lian-jie-du-tang, a traditional Chinese medicine prescription, induces cell-cycle arrest and apoptosis in human liver cancer cells in vitro and in vivo. J Gastroenterol Hepatol. 2008;23:e290-299.
[2[1]]Ohta Y, Sasaki E, Nishida K, et al. Preventive effect of oren-gedoku-to (huanglian-jie-du-tang) extract on progression of carbon tetrachloride-induced acute liver injury in rats. Am J Chin Med. 1997;25:57-68.
[22]European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Hepatol. 2017;67:370-398.
[23]Terrault N A, Bzowej N H, Chang K M, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283.
[24]Cheng X X, Wang H F, Yang J L, et al. Arctigenin protects against liver injury from acute hepatitis by suppressing immune cells in mice. Biomed Pharmacother. 2018;102:464-471.
[25]Wang J B, Liu R, Liu B X, et al. Systems Pharmacology-based strategy to screen new adjuvant for hepatitis B vaccine from Traditional Chinese Medicine Ophiocordyceps sinensis. Sci Rep. 2017;7:44788.
[26]Wang D P. Clinical study of Yinzhi Sanhuang Jiedu Decoction combined with entecavir in the treatment of chronic hepatitis B. Beijing University of Chinese Medicine. 2018;63-64.
[27]Liaw Y F, Leung N, Kao J H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283.
[28]State Bureau of Technical Supervision. National Standards for TCM Clinical Diagnosis and Treatment in the People's Republic of China: Symptoms Section. Beijing: China Standard Press. 1997;4:55.
[29]Chinese Society of Integrated Traditional and Western Medicine, Digestive System Diseases Committee. Consensus on diagnosis and treatment of cirrhosis with integrated traditional Chinese and Western medicine. Chinese Journal of Integrated Traditional and Western Medicine on Digestion. 2011;19:277-279.
[30]Tu T, Sandra B, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biological Chemistry. 2017;398:817-837.
[31] Terrault N A, Bzowej N H,Chang K M, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283.
[32] Liaw Y F, Kao J H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology International. 2012;6:531-561.
[33]Testoni B, Levrero M, Zoulim F. Challenges to a Cure for HBV Infection. Seminars in Liver Disease. 2017;37:231-242.
[34]Lok Anna S, Zoulim Fabien, Dusheiko Geoffrey, et al. Hepatitis B cure: From discovery to regulatory approval. J Hepatol. 2017;67:847-861.
[35]He M, Wu Y, Wang M M, et al. Meta-analysis of the clinical value of oxymatrine on sustained virological response in chronic hepatitis B. Ann Hepatol. 2016;15:482-491.
[36]Zhang L, Schuppan D. Traditional Chinese Medicine (TCM) for fibrotic liver disease: Hope and hype. Journal of Hepatology. 2014;61:166-168.
[37]Kang H, Zhao Y, Li C, et al. Integrating clinical indexes into four-diagnostic information contributes to the Traditional Chinese Medicine (TCM) syndrome diagnosis of chronic hepatitis B. Sci Rep. 2015;5:9395.
[38]Chen J X, Xu Q X, Wang J H, et al. A Case of Recurrent Hepatocellular Carcinoma Acquiring Complete Remission of Target Lesion With Treatment With Traditional Chinese Medicine. Integr Cancer Ther. 2017;16:597-604.
[39]Xiong X, Yang X, Liu Y, et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertension Research Official Journal of the Japanese Society of Hypertension. 2013;36:570-579.